1339 related articles for article (PubMed ID: 32880601)
21. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J; Rugo HS; Cescon DW; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Torregroza Otero M; Gokmen E; Loi S; Guo Z; Zhou X; Karantza V; Pan W; Schmid P;
N Engl J Med; 2022 Jul; 387(3):217-226. PubMed ID: 35857659
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Satake H; Lee KW; Chung HC; Lee J; Yamaguchi K; Chen JS; Yoshikawa T; Amagai K; Yeh KH; Goto M; Chao Y; Lam KO; Han SR; Shiratori S; Shah S; Shitara K
Jpn J Clin Oncol; 2023 Mar; 53(3):221-229. PubMed ID: 36533429
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
24. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ; Oh DY; Kato K; Arkenau T; Tabernero J; Correa MC; Zimina AV; Bai Y; Shi J; Lee KW; Wang J; Poddubskaya E; Pan H; Rha SY; Zhang R; Hirano H; Spigel D; Yamaguchi K; Chao Y; Wyrwicz L; Disel U; Cid RP; Fornaro L; Evesque L; Wang H; Xu Y; Li J; Sheng T; Yang S; Li L; Moehler M; Xu RH;
BMJ; 2024 May; 385():e078876. PubMed ID: 38806195
[TBL] [Abstract][Full Text] [Related]
25. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
27. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Chung HC; Kang YK; Chen Z; Bai Y; Wan Ishak WZ; Shim BY; Park YL; Koo DH; Lu J; Xu J; Chon HJ; Bai LY; Zeng S; Yuan Y; Chen YY; Gu K; Zhong WY; Kuang S; Shih CS; Qin SK
Cancer; 2022 Mar; 128(5):995-1003. PubMed ID: 34878659
[TBL] [Abstract][Full Text] [Related]
29. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Tabernero J; Bang YJ; Van Cutsem E; Fuchs CS; Janjigian YY; Bhagia P; Li K; Adelberg D; Qin SK
Future Oncol; 2021 Aug; 17(22):2847-2855. PubMed ID: 33975465
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Hattori M; Masuda N; Takano T; Tsugawa K; Inoue K; Matsumoto K; Ishikawa T; Itoh M; Yasojima H; Tanabe Y; Yamamoto K; Suzuki M; Pan W; Cortes J; Iwata H
Cancer Med; 2023 May; 12(9):10280-10293. PubMed ID: 36916728
[TBL] [Abstract][Full Text] [Related]
31. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
37. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
38. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
39. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
